Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.7 USD | -2.47% | -5.90% | -40.29% |
15/05 | HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating | MT |
14/05 | Transcript : Fennec Pharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.29% | 19Cr | |
+12.30% | 12TCr | |
+12.15% | 11TCr | |
-8.14% | 2.39TCr | |
-1.69% | 2.16TCr | |
-10.60% | 1.9TCr | |
-41.25% | 1.7TCr | |
-15.33% | 1.63TCr | |
+5.80% | 1.41TCr | |
+28.03% | 1.2TCr |
- Stock Market
- Equities
- FENC Stock
- News Fennec Pharmaceuticals Inc.
- Fennec Pharmaceuticals : Earnings Flash (FRX.TO) FENNEC PHARMACEUTICALS Posts Net loss for Q2 was US$4.0 million ($0.15 per share), compared to $4.8 million ($0.21 per share) for the same period in 202